Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.

Authors:
Christian Grommes
Christian Grommes
Case Western Reserve University
United States
Anas Younes
Anas Younes
Memorial Sloan Kettering Cancer Center
Rockville Centre | United States

Cancer Cell 2017 06 25;31(6):731-733. Epub 2017 May 25.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients with primary central nervous system lymphoma but was associated with significant toxicity, including pulmonary and cerebral aspergillosis infections.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.05.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572136PMC
June 2017
7 Reads

Publication Analysis

Top Keywords

lymphoma associated
4
temozolomide etoposide
4
ibrutinib induced
4
etoposide doxorubicin
4
combination temozolomide
4
demonstrate combination
4
induced frequent
4
et al demonstrate
4
associated toxicity
4
system lymphoma
4
doxorubicin dexamethasone
4
inhibitor ibrutinib
4
tyrosine kinase
4
central nervous
4
kinase btk
4
bruton tyrosine
4
rituximab bruton
4
primary central
4
dexamethasone rituximab
4
nervous system
4

Altmetric Statistics

Similar Publications

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Cancer Discov 2017 09 15;7(9):1018-1029. Epub 2017 Jun 15.

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.

Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown. We performed a phase I clinical trial with ibrutinib, the first-in-class BTK inhibitor, for patients with relapsed or refractory CNS lymphoma. Read More

View Article
September 2017

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Cancer Cell 2017 06 25;31(6):833-843.e5. Epub 2017 May 25.

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address:

Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR signaling and is particularly active in lymphomas with mutations altering the BCR subunit CD79B and MYD88. We performed a proof-of-concept phase Ib study of ibrutinib monotherapy followed by ibrutinib plus chemotherapy (DA-TEDDi-R). Read More

View Article
June 2017

Second-generation inhibitors of Bruton tyrosine kinase.

J Hematol Oncol 2016 09 2;9(1):80. Epub 2016 Sep 2.

Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.

Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Read More

View Article
September 2016

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Lancet Oncol 2014 Aug 17;15(9):1019-26. Epub 2014 Jul 17.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Ibrutinib, a novel oral Bruton's tyrosine kinase inhibitor, has shown single-drug activity in relapsed or refractory B-cell malignancies. We investigated the safety and efficacy of ibrutinib in combination with R-CHOP for patients with previously untreated CD20-positive B-cell non-Hodgkin lymphoma. Read More

View Article
August 2014